U.S. President Biden President Donald J. Trump releases a proclamation for September as National #Ovarian #Cancer Awareness Month. In the briefing, President Biden highlighted this "the deadliest of all female reproductive system cancers." and "...there remains no reliable method for asymptomatic

$COV confirms that U.S. clinical trials have commenced with first patients enrolled over 8 recruitment centres. The trial will validate the use of CLEO’s ovarian cancer blood test for the U.S. market. Sets pathway toward FDA submission in CY2025. Link to release:

$COV Quarterly Activities Report - September 2024. Cleo Diagnostics is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer. Link to release: bit.ly/40fSYNl #CleoDX #ovariancancer #ovarian #cancer #medtech

Video Replay: $COV Chief Scientific Officer, Dr Andrew Stephens presentation at Sydney Opera House Jane Morgan Management Investor Lunch outlining the clear need for the Company's simple blood test for the accurate and early diagnosis of ovarian cancer. Link to Video:

$COV further expands Ovarian Cancer trial with the inclusion of prominent women’s #ultrasound specialist Siles Health. Siles will provide important insights to support clinical implementation strategies for market adoption of CLEO’s ovarian cancer #bloodtest. Link to release:

February is #OvarianCancerAwarenessMonth. The stark reality is that Ovarian Cancer is the deadliest women’s cancer with only 49% of women surviving 5 years from diagnosis➡️compared to a 92% survival rate for breast cancer. Early and accurate detection is critical.

$COV commences technology transfer marking the completion of a critical milestone towards the commercial production of its first Ovarian Cancer diagnostic test. Development will be carried out by global leader in immunoassay technology, R&D Systems a subsidiary of Bio-Techne

$COV Quarterly Activities Report - March 2025. Cleo Diagnostics is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer. Link to release: bit.ly/4lvOVVs #CleoDX #ovariancancer #ovarian #cancer #medtech #womenshealth

$COV to fast track development of its Ovarian Cancer test with the signing of a Collaboration Agreement with University College London UCL to secure access to ~2,000 high-quality blood samples. Samples sourced from UKCTOCS, the world's largest Ovarian Cancer screening trial, to

$COV Dayna Louca outlines how the Collaboration Agreement signed with the University College London UCL to secure access to ~2,000 UKCTOCS samples will fast track development of its #Ovarian #Cancer test. #ovariancancer #medtech #womenshealth ASX.COV #invest

$COV Chief Scientific Officer, Dr Andrew Stephens, joins Andrew Geoghegan Andrew Geoghegan of ausbiz to discuss the importance of the partnership with the University College London UCL to access 2000 UKCTOCS biobank samples. The significance of utilising samples from the

$COV advances commercial product development following the completion of alpha testing using commercial prototypes of CLEO’s Ovarian Cancer pre-surgical triage assay kits. Testing was conducted at CLEO’s laboratory and confirmed: ▪️Robust and reproducible performance of all

$COV shares its updated June 2025 corporate presentation outlining the Company's strategy and progress on "Pioneering the Transformation of Ovarian Cancer Detection" The clinical unmet need for a screening solution for Ovarian Cancer is urgent. Critically, no effective

$COV Chief Executive, Richard Allman, and Chief Scientist, Dr Andrew Stephens to present at an Investor Webinar to provide an update on the Company’s progress and commercialisation pathway for its simple blood test for the accurate and early detection of Ovarian Cancer.

Reminder to register for the Cleodx Investor Webinar tomorrow. Registration link: bit.ly/COVwebinarJun25 Cleo Diagnostics Investor Webinar 📆 Wednesday, 25 June 2025 ⏲️ 11am AEST The event will be hosted by Cleo's Head of Corporate Development, Dayna Louca -

$COV strengthens its planned FDA Submission following approval from U.S. National Cancer Institute (NCI) to access blood samples from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. CLEO will use samples from PLCO biobank to: ▪️Generate data to

Video Replay: $COV Investor Webinar of 25 June. The webinar features updates on the Company’s progress and commercialisation pathway for its simple blood test for the accurate and early detection of Ovarian Cancer. Link to video: bit.ly/469gVsT #CleoDX

$COV Quarterly Activities Report - June 2025. Cleo Diagnostics is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer. Link to release: bit.ly/45dw3nS #CleoDX #ovariancancer #ovarian #cancer #medtech #womenshealth

$COV commences Health Economic Study to support U.S. market entry. ▪ Partnership with EntityRisk to provide evidence-based insight into the economic value of Cleo’s Ovarian Cancer Pre-Surgical Test in the U.S. ▪ Partnership with Norstella to examine detailed physician and